Recent advances in treating cognitive impairment in schizophrenia

Psychopharmacology

Volumn 202, Issue 1-3, 2009, Pages 259-273

  Galletly, Cherrie ^a  

^a Adelaide Clinic   (Australia)

Author keywords

Antipsychotic; Cholinergic; CNTRICS; Dopamine; Galantamine; Glutamate; MATRICS; Modafanil; Neuropsychological; NMDA

Indexed keywords

4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; ADROGOLIDE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; BUNGAROTOXIN RECEPTOR; BUSPIRONE; CLOZAPINE; DAR 0100; DIHYDREXIDINE; DIZOCILPINE; DONEPEZIL; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EGLUMETAD; GALANTAMINE; GLUTAMIC ACID; GUANFACINE; KAINIC ACID RECEPTOR; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; NICOTINE; RIVASTIGMINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG RESEARCH; GABAERGIC SYSTEM; HUMAN; LEARNING; MEMORY; NEUROBIOLOGY; NEUROMODULATION; NEUROPSYCHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOPAMINE AGENTS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN AGENTS;

EID: 59449089044     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-008-1302-9     Document Type: Review

References (179)

1. LE Adler LD Hoffer A Wiser R Freedman 1993 Normalization of auditory physiology by cigarette smoking in schizophrenic patients Am J Psychiatry 150 1856 1861
2. M Akil JN Pierri RE Whitehead CL Edgar C Mohila AR Sampson DA Lewis 1999 Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects Am J Psychiatry 156 1580 1589
3. M Akil BS Kolachana DA Rothmond TM Hyde DR Weinberger JE Kleinman 2003 Catechol-O-Methyltransferase genotype and dopamine regulation in the human brain J Neurosci 23 2008 2013
4. F Alves M Figee T van Amelsvoort D Veltman L de Haan 2008 The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication Psychopharmacol Bull 41 121 132
5. JS Ballon D Feifel 2006 A systematic review of modafinil: potential clinical uses and mechanisms of action J Clin Psychiatry 67 554 566
6. DM Barch CS Carter 2005 Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers Schizophr Res 77 43 58
7. DM Barch CS Carter the CNTRICS Executive Committee 2008 Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative Schizophr Bull 34 613 618
8. ME Bardgett M Points C Ramsey-Faulkner J Topmiller J Roflow T McDaniel T Lamontagne MS Griffith 2008 The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss Neuropsychopharmacology 33 1980 1991
9. JH Barnett L Scoriels MR Munafò 2008 Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism Biol Psychiatry 64 137 144
10. RS Barr MA Culhane LE Jubelt RS Mufti MA Dyer AP Weiss T Deckersbach JF Kelly O Freudenreich DC Goff AE Evins 2008 The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls Neuropsychopharmacology 33 480 490
11. RM Bilder RS Goldman D Robinson G Reiter L Bell J Bates E Pappadopulos DF Willson JM Alvir MG Woerner S Geisler JM Kane JA Lieberman 2000 Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates Am J Psychiatry 157 549 559
12. J Birks 2006 Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst Rev 1 CD005593
13. C Boast AC Bartolomeo H Morris JA Moyer 1999 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats Neurobiol Learn Mem 71 259 271
14. NC Bodick WW Offen AI Levey NR Cutler SG Gauthier A Satlin HE Shannon GD Tollefson K Rasmussen FP Bymaster DJ Hurley WZ Potter SM Paul 1997 Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease Arch Neurol 54 465 473
15. E Bora B Veznedaroglu B Kayahan 2005 The effect of galantamine added to clozapine on cognition of five patients with schizophrenia Clin Neuropharmacol 28 139 141
16. CR Breese MJ Lee CE Adams B Sullivan J Logel KM Gillen MJ Marks AC Collins S Leonard 2000 Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia Neuropsychopharmacology 23 351 364
17. CA Briggs DJ Anderson JD Brioni JJ Buccafusco MJ Buckley JE Campbell MW Decker D Donnelly-Roberts RL Elliot M Gopalakrishnan MW Holladay Y-H Hui WJ Jackson DJB Kim KC Marsh A O'Neill MA Prendergast KB Ryther JP Sullivan SP Arneric 1996 Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo Pharmacol Biochem Behav 57 231 241
18. A Brockhaus-Dumke F Schultze-Lutter R Mueller I Tendolkar A Bechdolf R Pukrop J Klosterkoetter S Ruhrmann 2008 Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients Biol Psychiatry 64 5 376 384
19. KE Browman P Curzon JB Pan AL Molesky VA Komater MW Decker JD Brioni RB Moreland GB Fox 2005 A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats Pharmacol Biochem Behav 82 148 155
20. RW Buchanan R Freedman DC Javitt A Abi-Dargham JA Lieberman 2007 Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia Schizophr Bull 33 1120 1130
21. RW Buchanan DC Javitt SR Marder NR Schooler JM Gold RP McMahon U Heresco-Levy WT Carpenter 2007 The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments Am J Psychiatry 164 1593 1602
22. RW Buchanan RR Conley D Dickinson MP Ball S Feldman JM Gold RP McMahon 2008 Galantamine for the treatment of cognitive impairments in people with schizophrenia Am J Psychiatry 165 82 89
23. FP Bymaster C Felder S Ahmed D McKinzie 2002 Muscarinic receptors as a target for drugs treating schizophrenia Curr Drug Targets CNS Neurol Disord 1 163 181
24. A Carlsson 1977 Does dopamine play a role in schizophrenia? Psychol Med 7 583 597
25. CS Carter 2005 Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia Schizophr Bull 31 810 815
26. CS Carter DM Barch RW Buchanan E Bullmore JH Krystal J Cohen M Geyer M Green KH Nuechterlein T Robbins S Silverstein EE Smith M Strauss T Wykes R Heinssen 2008 Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative Biol Psychiatry 64 4 10
27. A Caspi TE Moffitt M Cannon J McClay R Murray H Harrington A Taylor L Arseneault B Williams A Braithwaite R Poulton IW Craig 2005 Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction Biol Psychiatry 57 1117 1127
28. G Cassens AK Inglis PS Appelbaum TG Gutheil 1990 Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients Schizophr Bull 16 477 499
29. SA Castner GV Williams PS Goldman-Rakic 2000 Reversal of antipsychotic-induced working memory deficits by short term dopamine D1 receptor stimulation Science 287 2020 2022
30. DM Censits JD Ragland RC Gur RE Gur 1997 Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study Schizophr Res 24 289 298
31. ML Chew BH Mulsant BG Pollock ME Lehman A Greenspan MA Kirshner RR Bies S Kapur G Gharabawi 2006 A model of anticholinergic activity of atypical antipsychotic medications Schizophr Res 88 63 72
32. S Chouinard E Stip J Poulin JP Melun R Godbout F Guillem H Cohen 2007 Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits Curr Med Res Opin 23 575 583
33. MH Corrigan CC Gallen ML Bonura KM Merchant 2004 Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial Biol Psychiatry 55 445 451
34. I Creese DR Burt SH Snyder 1976 Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 192 481 483
35. AS David A Malmberg L Brandt P Allebeck G Lewis 1997 IQ and risk for schizophrenia: a population-based cohort study Psychol Med 27 1311 1323
36. MA Davies BA Compton-Toth SJ Hufeisen HY Meltzer BL Roth 2004 The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl) 178 451 460
37. B Dean M McLeod D Keriakous J McKenzie E Scarr 2002 Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia Mol Psychiatry 7 1083 1091
38. CM de Fiebre EM Meyer JC Henry SI Muraskin WR Kem RL Papke 1995 Characterization of a series of anabaseine derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha7/125 i-alpha-bungarotoxin receptor subtypes Mol Pharmacol 47 164 171
39. SL de Haas SJ de Visser JP van der Post M de Smet RC Schoemaker B Rijnbeek AF Cohen JM Vega NGB Agrawal TV Goel RC Simpson LK Pearson S Li M Hesney MG Murphy JMA Van Gerven 2006 Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA a2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers J Psychopharmacol 21 374 383
40. J deLeon FJ Diaz 2005 A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors Schizophr Res 76 135 157
41. V De Luca AH Wong DJ Muller GW Wong RF Tyndale JL Kennedy 2004 Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients Neuropsychopharmacology 29 1522 1526
42. F Dickerson JJ Boronow N Ringel F Parente 1999 Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up Schizophr Res 37 13 20
43. DJ Done TJ Crow EC Johnstone A Sacker 1994 Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11 Br Med J 309 699 703
44. R Dutta T Greene J Addington K McKenzie M Phillips RM Murray 2007 Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis Schizophr Bull 33 868 876
45. MA Dyer O Freudenreich MA Culhane GN Pachas T Deckersbach E Murphy DC Goff AE Evins 2008 High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia Schizophr Res 102 1-3 88 95
46. CD Field CA Galletly D Anderson P Walker 1997 Computer-aided cognitive rehabilitation: possible application to the attentional deficit of schizophrenia A report of negative results. Percept Mot Skills 85 995 1002
47. RB Fields DP Van Kammen JL Peters J Rosen WB Van Kammen A Nugent M Stipetic M Linnoila 1988 Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings Schizophr Res 1 417 423
48. S Frangou M Hadjulis A Vourdas 2008 The Maudsley Early Onset Schizophrenia Study: cognitive function over a 4-year follow-up period Schizophr Bull 34 52 59
49. A Fredrickson PJ Snyder J Cromer E Thomas M Lewis P Maruff 2008 The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine Hum Psychopharmacol 23 5 425 436
50. R Freedman M Hall LE Adler S Leonard 1995 Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia Biol Psychiatry 38 22 33
51. R Freedman H Coon M Myles-Worsley A Orr-Urtreger A Olincy A Davis M Polymeropoulos J Holik J Hopkins M Hoff J Rosenthal MC Waldo F Reimherr P Wender J Yaw DA Young CR Breese CE Adams D Patterson LE Adler L Kruglyak S Leonard W Byerley 1997 Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus Proc Natl Acad Sci USA 94 587 592
52. R Freedman S Leonard M Waldo J Gault A Olincy LE Adler 2006 Characterization of allelic variants at chromosome 15q14 in schizophrenia Genes Brain Behav 5 Suppl 1 14 22
53. R Freedman A Olincy RW Buchanan JG Harris JM Gold L Johnson D Allensworth A Guzman-Bonilla B Clement MP Ball J Kutnick V Pender LF Martin KE Stevens BD Wagner GO Zerbe F Soti WR Kem 2008 Initial phase 2 trial of a nicotinic agonist in schizophrenia Am J Psychiatry 165 1040 1047
54. JI Friedman 2004 Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists Psychopharmacology 174 45 53
55. JI Friedman DN Adler HD Temporini E Kemether PD Harvey L White M Parrella KL Davis 2001 Guanfacine treatment of cognitive impairment in schizophrenia Neuropsychopharmacology 25 402 409
56. JI Friedman DN Adler E Howanitz PD Harvey G Brenner H Temporini L White M Parrella KL Davis 2002 A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia Biol. Psychiatry 51 349 357
57. ML Furey P Pietrini JV Haxby 2000 Cholinergic enhancement and increased selectivity of perceptual processing during working memory Science 290 2315 2319
58. CA Galletly CR Clark AC McFarlane 2000 Treating cognitive dysfunction in patients with schizophrenia J Psychiatry Neurosci 25 117 124
59. CA Galletly CR Clark AC McFarlane 2005 Clozapine improves working memory updating in schizophrenia Eur Neuropsychopharmacol 15 601 608
60. CA Galletly AC McFarlane CR Clark 2007 Impaired updating of working memory in schizophrenia Int J Psychophysiol 63 265 274
61. M Gasparini E Fabrizio V Bonifati G Meco 1997 Cognitive improvement during Tolcapone treatment in Parkinson's disease J Neural Transm 104 887 894
62. MS George CE Molnar EL Grenesko B Anderson Q Mu K Johnson Z Nahas M Knable P Fernandes J Juncos X Huang DE Nichols RB Mailman 2007 A single 20mg dose of dihydrexidine (DAR-0100), a full dopamine D (1) agonist, is safe and tolerated in patients with schizophrenia Schizophr Res 93 42 50
63. DC Goff L Leahy I Berman T Posever L Herz AC Leon SA Johnson G Lynch 2001 A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia J Clin Psychopharmacol 21 484 487
64. DC Goff R Keefe L Citrome K Davy JH Krystal C Large TR Thompson J Volavka EL Webster 2007 Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials J Clin Psychopharmacol 27 582 589
65. DC Goff JS Lamberti AC Leon MF Green AL Miller J Patel T Manschreck O Freudenreich SA Johnson 2008 A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia Neuropsychopharmacology 33 465 472
66. TE Goldberg MF Egan T Gscheidle R Coppola T Weickert BS Kolachana D Goldman DR Weinberger 2003 Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia Arch Gen Psychiatry 60 889 896
67. TE Goldberg RS Goldman KE Burdick AK Malhotra T Lencz RC Patel MG Woerner NR Schooler JM Kane DG Robinson 2007 Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64 1115 1122
68. MF Green 1996 What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153 321 330
69. MF Green 2007 Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions Am J Psychiatry 164 992 994
70. MF Green BD Marshall Jr WC Wirshing D Ames SR Marder S McGurk RS Kern J Mintz 1997 Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154 799 804
71. MF Green RS Kern DL Braff J Mintz 2000 Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26 119 136
72. MF Green KH Nuechterlein RS Kern LE Baade WS Fenton JM Gold RS Keefe R Mesholam-Gately LJ Seidman E Stover SR Marder 2008 Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS psychometric and standardization study Am J Psychiatry 165 221 228
73. JM Griffith J O'Neill F Petty D Garver D Young R Freedman 1998 Nicotinic receptor desensitization and sensory gating deficits in schizophrenia Biol Psychiatry 44 98 106
74. RE Hampson G Rogers G Lynch SA Deadwyler 1998 Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance J Neurosci 18 2740 2747
75. PJ Harrison 2008 Metabotropic glutamate receptor agonists for schizophrenia Br J Psychiatry 192 86 87
76. PD Harvey B Cornblatt 2008 Pharmacological treatment of cognition in schizophrenia: an idea whose method has come Am J Psychiatry 165 163 165
77. PD Harvey CR Bowie JI Friedman 2001 Cognition in schizophrenia Curr Psychiatry Rep 3 423 428
78. PD Harvey J Rabinowitz M Eerdekens M Davidson 2005 Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial Am J Psychiatry 162 1888 1895
79. GE Hogarty S Flesher R Ulrich M Carter D Greenwald M Pogue-Geile M Kechavan S Cooley AL DiBarry A Garrett H Parepally R Zoretich 2004 Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior Arch Gen Psychiatry 61 866 876
80. EA Holthausen D Wiersma W Cahn PM Kahn RS Dingemans AH Schene R Van Den Bosch 2007 Predictive value of cognition for different domains of outcome in recent-onset schizophrenia Psychiatry Res 149 71 80
81. MD Hunter V Ganesan ID Wilkinson SA Spence 2006 Impact of modafinil on prefrontal executive function in schizophrenia Am J Psychiatry 163 2184 2186
82. J Ichikawa J Dai IA O'Laughlin WL Fowler HY Meltzer 2002 Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum Neuropsychopharmacology 26 325 339
83. DC Javitt 2008 Glycine Transport Inhibitors and the Treatment of Schizophrenia Biol Psychiatry 63 6 8
84. DC Javitt L Duncan A Balla H Sershen 2005 Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action Mol Psychiatry 10 275 287
85. P Jones B Rodgers R Murray M Marmot 1994 Child development risk factors for adult schizophrenia in the British 1946 birth cohort Lancet 344 1398 1402
86. RS Kahn WW Fleischhacker H Boter M Davidson Y Vergouwe IP Keet MD Gheorghe JK Rybakowski S Galderisi J Libiger M Hummer S Dollfus JJ López-Ibor LG Hranov W Gaebel J Peuskens N Lindefors A Riecher-Rössler DE Grobbee EUFEST study group 2008 Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial Lancet 371 1085 1097
87. SK Keedy CL Ebens MS Keshavan JA Sweeney 2006 Functional magnetic resonance imaging studies of eye movements in first episode schizophrenia: smooth pursuit, visually guided saccades and the oculomotor delayed response task Psychiatry Res 146 199 211
88. RS Keefe WS Fenton 2007 How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 33 912 920
89. RS Keefe SG Silva DO Perkins JA Lieberman 1999 The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis Schizophr Bull 25 201 222
90. RS Keefe M Poe TM Walker JW Kang PD Harvey 2006 The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity Am J Psychiatry 163 426 432
91. RS Keefe RM Bilder SM Davis PD Harvey BW Palmer JM Gold HY Meltzer MF Green G Capuano TS Stroup JP McEvoy MS Swartz RA Rosenheck DO Perkins CE Davis JK Hsiao JA Lieberman CATIE Investigators; Neurocognitive Working Group 2007a Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial Arch Gen Psychiatry 64 633 647
92. RS Keefe JA Sweeney H Gu RM Hamer DO Perkins JP McEvoy JA Lieberman 2007 Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison Am J Psychiatry 164 1061 1071
93. RS Keefe AK Malhotra HY Meltzer JM Kane RW Buchanan A Murthy M Sovel C Li R Goldman 2008 Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial Neuropsychopharmacology 33 1217 1228
94. C Kelly RG McCreadie 1999 Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland Am J Psychiatry 156 1751 1757
95. RE Kelly Jr LJ Cohen RJ Semple P Bialer A Lau A Bodenheimer E Neustadter A Barenboim II Galynker 2006 Relationship between drug company funding and outcomes of clinical psychiatric research Psychol Med 36 1647 1656
96. RS Kern KH Nuechterlein MF Green LE Baade WS Fenton RSE Gold JM Keefe R Mesholam-Gately J Mintz LJ Seidman E Stover SR Marder 2008 The MATRICS consensus cognitive battery, part 2: co-norming and standardization Am J Psychiatry 165 214 220
97. MS Kramer B Last A Getson SA Reines 1997 The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia D4 Dopamine Antagonist Group. Arch Gen Psychiatry 54 567 572
98. MS Kraus RS Keefe 2007 Cognition as an outcome measure in schizophrenia Br J Psychiatry 191 Suppl. 50 s46 s51
99. SW Lee JG Lee BJ Lee YH Kim 2007 A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia Int Clin Psychopharmacol 22 63 68
100. JA Lieberman BB Sheitman BJ Kinon 1997 Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity Neuropsychopharmacology 17 205 229
101. JA Lieberman TS Stroup JP McEvoy MS Swartz RA Rosenheck DO Perkins RS Keefe SM Davis CE Davis BD Lebowitz J Severe JK Hsiao Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators 2005 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209 1023
102. R Liljequist A Haapalinna M Ahlander YH Li PT Mannisto 1997 Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats Behav Brain Res 82 195 202
103. RE Litman TP Su WZ Potter WW Hong D Pickar 1996 Idazoxan and response to typical neuroleptics in treatment resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine Br J Psychiatry 168 571 579
104. Maccabe JH (2008) Population-based cohort studies on premorbid cognitive function in schizophrenia. Epidemiol Rev (in press)
105. TC Manschreck RA Boshes 2007 The CATIE schizophrenia trial: results, impact, controversy Harv Rev Psychiatry 15 245 258
106. VS Mattay TE Goldberg F Fera AR Hariri A Tessitore MF Egan B Kolachana JH Callicott DR Weinberger 2003 Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine Proc Natl Acad Sci U S A 100 6186 6191
107. JP McEvoy O Freudenreich W Wilson 1999 Smoking and therapeutic response to clozapine in patients with schizophrenia Biol Psychiatry 46 125 129
108. SR McGurk HY Meltzer 2000 The role of cognition in vocational functioning in schizophrenia Schizophr Res 45 175 184
109. SR McGurk KT Mueser D Walling PD Harvey HY Meltzer 2004 Cognitive functioning predicts outpatient service utilization in schizophrenia Ment Health Serv Res 6 185 188
110. SR McGurk EW Twamley DI Sitzer GJ McHugo KT Mueser 2007 A meta-analysis of cognitive remediation in schizophrenia Am J Psychiatry 164 1791 1802
111. Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Retrieved December 27, 2007 from http://www.matrics.ucla.edu/
112. A Medalia J Gold A Merriam 1988 The effects of neuroleptics on neuropsychological test results in schizophrenia Arch Clin Neuropsychol 3 249 271
113. HY Meltzer SR McGurk 1999 The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia Schizophr Bull, 25 233 255
114. HY Meltzer SM Stahl 1976 The dopamine hypothesis of schizophrenia: a review Schizophr Bull 2 19 76
115. FS Menniti TA Chappie JM Humphrey CJ Schmidt 2007 Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia Curr Opin Investig Drugs 8 54 59
116. EM Meyer ET Tay RL Papke C Meyers GL Huang CM de Fiebre 1997 3-2,4-Dimethoxybenzylidene-anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memoryrelated behaviors in a mecamylamine-sensitive manner Brain Res 768 49 56
117. P Milev BC Ho S Arndt NC Andreasen 2005 Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up Am J Psychiatry 162 495 506
118. AL Mishara TE Goldberg 2004 A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book Biol Psychiatry 55 1013 1022
119. S Morein-Zamir DC Turner BJ Sahakian 2007 A review of the effects of modafinil on cognition in schizophrenia Schizophr Bull 33 1298 1306
120. A Mouri Y Noda T Enomoto T Nabeshima 2007 Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment Neurochem Int 51 173 184
121. KT Mueser SR McGurk 2004 Schizophrenia Lancet 363 2063 2072
122. HT Nagamoto LE Adler KA McRae P Huettl E Cawthra G Gerhardt R Hea J Griffith 1999 Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4- hydroxyphenylglycol Neuropsychobiology 39 10 17
123. U Noren A Bjorner O Sonesson L Eriksson 2006 Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophr Res 85 302 304
124. KH Nuechterlein DM Barch JM Gold TE Goldberg MF Green RK Heaton 2004 Identification of separable cognitive factors in schizophrenia Schizophr Res 72 29 39
125. KH Nuechterlein MF Green RS Kern LE Baade DM Barch JD Cohen S Essock WS Fenton FJ Frese 3rd JM Gold T Goldberg RK Heaton RS Keefe H Kraemer R Mesholam-Gately LJ Seidman E Stover DR Weinberger AS Young S Zalcman SR Marder 2008 The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity Am J Psychiatry 165 203 213
126. A Olincy JG Harris LL Johnson V Pender S Kongs D Allensworth J Ellis GO Zerbe S Leornard KE Stevens JO Stevens L Martin LE Adler F Soti WR Kem R Freedman 2006 Proof-of-Concept Trial of an alpha7 Nicotinic Agonist in Schizophrenia Arch Gen Psychiatry 63 630 638
127. MJ Owen NM Williams MC O'Donovan 2004 The molecular genetics of schizophrenia: new findings promise new insights Mol Psychiatry 9 14 27
128. BA Palmer RK Heaton JA Glaksjo JD Evans TL Patterson S Golshan DV Jeste 2002 Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving Schizophr Res 55 205 215
129. O Perl RD Strous A Dranikov R Chen S Fuchs 2006 Low levels of alpha7-nicotinic acetylcholine receptor mRNA on peripheral blood lymphocytes in schizophrenia and its association with illness severity Neuropsychobiology 53 88 93
130. RH Perlis CS Perlis Y Wu C Hwang M Joseph AA Nierenberg 2005 Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry Am J Psychiatry 162 1957 1960
131. KW Perry LK Nisenbaum CA George HE Shannon CC Felder FP Bymaster 2001 The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex Biol Psychiatry 49 716 725
132. LJ Porrino JB Daunais GA Rogers RE Hampson SA Deadwyler 2005 Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates PLoS Biol 3 e299
133. M Poyurovsky D Koren I Gonopolsky M Schneidman C Fuchs A Weizman R Weizman 2003 Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study Eur Neuropsychopharmacol 13 123 128
134. SK Praharaj P Verma D Roy A Singh 2005 Is clonidine useful for treatment of clozapine-induced sialorrhea? J Psychopharmacol 19 426 428
135. JA Pratt C Winchester A Egerton SM Cochran BJ Morris 2008 Modelling prefrontal cortex deficits in schizophrenia: implications for treatment Br J Pharmacol 153: Suppl 1 S465 S470
136. O Puig R Penadés C Gastó R Catalán A Torres M Salamero 2008 Verbal memory, negative symptomatology and prediction of psychosocial functioning in schizophrenia Psychiatry Res. 2008 158 11 17
137. SE Purdon A Malla A Labelle W Lit 2001 Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol J Psychiatry Neurosci 26 137 149
138. TJ Raedler MB Knable DW Jones RA Urbina JG Gorey KS Lee MF Egan R Coppola DR Weinberger 2003 In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia Am J Psychiatry 160 118 127
139. TJ Raedler FP Bymaster R Tandon D Copolov B Dean 2007 Towards a muscarinic hypothesis of schizophrenia Mol Psychiatry 12 232 246
140. JD Ragland J Yoon MJ Minzenberg CS Carter 2007 Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism Int Rev Psychiatry 19 417 427
141. BL Roth SM Hanizavareh AE Blum 2004 Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders Psychopharmacology (Berl) 174 17 24
142. KA Sacco A Termine A Seyal MM Dudas JC Vessicchio S Krishnan-Sarin PI Jatlow BE Wexler TP George 2005 Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms Arch Gen Psychiatry 62 649 659
143. AJ Saykin DL Shtasel RE Gur DB Kester LH Mozley P Stafiniak RC Gur 1994 Neuropsychological deficits in neuroleptic naive patients with first-episode Schizophrenia Arch Gen Psychiatry 51 124 131
144. Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2008) Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry (in press)
145. MH Schubert KA Young PB Hicks 2006 Galantamine improves cognition in schizophrenic patients stabilized on risperidone Biol Psychiatry 60 530 533
146. MJ Sergi Y Rassovsky KH Nuechterlein MF Green 2006 Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia Am J Psychiatry 163 448 454
147. EG Severance RH Yolken 2008 Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia Genes Brain Behav 7 37 45
148. HE Shannon K Rasmussen FP Bymaster JC Hart SC Peters MD Swedberg L Jeppesen MJ Sheardown P Sauerberg A Fink-Jensen 2000 Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice Schizophr Res 42 249 259
149. S Silverstein LS Schenkel C Valone SW Nuernberger 1998 Cognitive deficits and psychiatric rehabilitation outcomes in schizophrenia Psychiatr Quart 69 169 191
150. JK Simosky KE Stevens LE Adler R Freedman 2003 Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism Psychopharmacology 165 386 396
151. EE Smith J Jonides 1999 Storage and executive processes in the frontal lobes Science 283 1657 1661
152. RC Smith J Warner-Cohen M Matute E Butler E Kelly S Vaidhyanathaswamy A Khan 2006 Effects of nicotine nasal spray on cognitive function in schizophrenia Neuropsychopharmacology 31 637 643
153. ML Steinberg JM Williams DM Ziedonis 2004 Financial implications of cigarette smoking among individuals with schizophrenia Tob Control 13 206
154. J Stirling C White S Lewis R Hopkins D Tantam A Huddy L Montague 2003 Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up study of an epidemiological cohort Schizophr Res 65 75 86
155. Stone JM, Davis JM, Leucht S, Pilowsky LS (2008) Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs-an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull (in press)
156. RD Strous R Maayan R Lapidus R Stryjer M Lustig M Kotler A Weizman 2003 Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia Arch Gen Psychiatry 60 133 141
157. T Sumiyoshi M Matsui S Nohara I Yamashita M Kurachi C Sumiyoshi K Jayathilake HY Meltzer 2001 Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment Am J Psychiatry 158 1722 1725
158. T Sumiyoshi S Park K Jayathilake A Roy A Ertugrul HY Meltzer 2007 Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study Schizophr Res 95 158 168
159. A Szöke A Trandafir 2008 Longitudinal studies of cognition in schizophrenia: meta-analysis Br J Psychiatry 192 248 257
160. H Tan JH Callicott DR Weinberger 2007 Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia Cerebral Cortex 17Suppl 1 i171 i181
161. HY Tan Q Chen TE Goldberg VS Mattay A Meyer-Lindenberg DR Weinberger JH Callicott 2007 Catechol-O-methyltransferase Val158Met modulation of prefrontal-parietal-striatal brain systems during arithmetic and temporal transformations in working memory J Neurosci 27 13393 133401
162. R Tandon MS Keshavan HA Nasrallah 2008 Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology Schizophr Res 102 1 18
163. AV Terry Jr SP Mahadik 2007 Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism J Pharmacol Exp Ther 320 961 968
164. Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) Retrieved December 27, 2007 from http://www.turns.ucla.edu/
165. DC Turner RW Robbins L Clark AR Aron J Dowson BJ Sahakian 2003 Cognitive enhancing effects of modafinil in healthy volunteers Psychopharmacology 165 260 269
166. DC Turner L Clark J Dowson TW Robbins BJ Sahakian 2004 Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder Biol Psychiatry 55 1031 1040
167. DC Turner L Clark E Pomarol-Clotet P McKenna TW Robbins BJ Sahakian 2004 Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia Neuropsychopharmacology 29 1363 1373
168. GB Varty VP Bakshi MA Geyer 1999 M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats Neuropsychopharmacology 20 311 321
169. D Velligan CC Bow-Thomas R Mahurin AL Miller LC Halgunseth 2000 Do specific neurocognitive deficits predict specific domains of function in schizophrenia? J Nerv Ment Dis 288 518 524
170. H Verdoux F Liraud F Assens F Abalan J van Os 2002 Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients Schizophr Res 56 149 159
171. JL Waddington HA Youssef 1996 Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia Psychol Med 26 681 688
172. D Wang Y Noda Y Zhou A Nitta H Furukawa T Nabeshima 2007 Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission Neuropharmacology 53 379 389
173. P Watkins 2000 COMT inhibitors and liver toxicity Neurology 55 S51 S52
174. DM Weiner ES Burstein N Nash GE Croston EA Currier KE Vanover SC Harvey E Donohue HC Hansen CM Andersson TA Spalding DF Gibson K Krebs-Thomson SB Powell MA Geyer U Hacksell Brann 2001 MR.5-hydroxytryptamine2A receptor inverse agonists as antipsychotics J Pharmacol Exp Ther 299 268 276
175. E Wezenberg RJ Verkes GS Ruigt W Hulstijn BG Sabbe 2007 Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers Neuropsychopharmacology 32 1272 1283
176. ND Woodward K Jayathilake HY Meltzer 2007 COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia Schizophr Res 90 86 96
177. T Wykes C Reeder S Landau B Everitt M Knapp A Patel R Romeo 2007 A randomized controlled trial of cognitive remediation Br J Psychiatry 190 421 427
178. K Yui K Goto S Ikemoto T Ishiguro B Angrist GE Duncan BB Sheitman JA Lieberman SH Bracha SF Ali 1999 Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization Mol Psychiatry 4 512 523
179. R Zoccali MR Muscatello A Bruno R Cambria U Micò E Spina M Meduri 2007 The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study Schizophr Res 93 109 116